Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • Aging (Upcoming)
    • Next-Generation Sequencing in Medicine (Jun 2022)
    • New Therapeutic Targets in Cardiovascular Diseases (Mar 2022)
    • Immunometabolism (Jan 2022)
    • Circadian Rhythm (Oct 2021)
    • Gut-Brain Axis (Jul 2021)
    • Tumor Microenvironment (Mar 2021)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Commentaries
    • Concise Communication
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • In-Press Preview
  • Commentaries
  • Concise Communication
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
M-current preservation contributes to anticonvulsant effects of valproic acid
Hee Yeon Kay, … , Anastasia Kosenko, Naoto Hoshi
Hee Yeon Kay, … , Anastasia Kosenko, Naoto Hoshi
Published September 8, 2015
Citation Information: J Clin Invest. 2015;125(10):3904-3914. https://doi.org/10.1172/JCI79727.
View: Text | PDF
Research Article Neuroscience

M-current preservation contributes to anticonvulsant effects of valproic acid

  • Text
  • PDF
Abstract

Valproic acid (VPA) has been widely used for decades to treat epilepsy; however, its mechanism of action remains poorly understood. Here, we report that the anticonvulsant effects of nonacute VPA treatment involve preservation of the M-current, a low-threshold noninactivating potassium current, during seizures. In a wide variety of neurons, activation of Gq-coupled receptors, such as the m1 muscarinic acetylcholine receptor, suppresses the M-current and induces hyperexcitability. We demonstrated that VPA treatment disrupts muscarinic suppression of the M-current and prevents resultant agonist-induced neuronal hyperexcitability. We also determined that VPA treatment interferes with M-channel signaling by inhibiting palmitoylation of a signaling scaffold protein, AKAP79/150, in cultured neurons. In a kainate-induced murine seizure model, administration of a dose of an M-channel inhibitor that did not affect kainate-induced seizure transiently eliminated the anticonvulsant effects of VPA. Retigabine, an M-channel opener that does not open receptor-suppressed M-channels, provided anticonvulsant effects only when administered prior to seizure induction in control animals. In contrast, treatment of VPA-treated mice with retigabine induced anticonvulsant effects even when administered after seizure induction. Together, these results suggest that receptor-induced M-current suppression plays a role in the pathophysiology of seizures and that preservation of the M-current during seizures has potential as an effective therapeutic strategy.

Authors

Hee Yeon Kay, Derek L. Greene, Seungwoo Kang, Anastasia Kosenko, Naoto Hoshi

×

Figure 1

VPA attenuated muscarinic suppression of the M-current and prevented oxo-M–induced hyperexcitability in cultured SCG and hippocampal neurons.

Options: View larger image (or click on image) Download as PowerPoint
VPA attenuated muscarinic suppression of the M-current and prevented oxo...
(A) Representative voltage-clamp current traces from SCG neurons (top) and pooled results (bottom) showing M-current suppression by 0.1 μM oxo-M and its disruption by 500 μM VPA pretreatment. Amplitudes of the M-currents are normalized to those at t = 0. Black box indicates presence of 0.1 μM oxo-M. (B) Summary of muscarinic suppression of the M-current at t = 1 min including results shown in A. Muscarinic suppression is attenuated by 500 μM VPA but not by 500 μM valeric acid, 100 μM vigabatrin, or 100 μM phenytoin. **P < 0.01 using Kruskal-Wallis one-way ANOVA followed by Dunn’s multiple comparisons test. Numbers above bars represent n values. (C) Current clamp traces showing action potential firing in response to 50 pA current injection. Traces from VPA-nontreated (top), 500 μM VPA–treated (middle), and 500 μM valeric acid–treated (bottom) hippocampal neurons are shown. Control, presence of 1 μM oxo-M, or presence of 20 μM XE991. (D and E) Input-excitation relationships from hippocampal neurons before (open circle) and after application of oxo-M (filled circle) from nontreated neurons (D) or 500 μM VPA–treated neurons (E). (F) Summary of neural firing by 50 pA current injection shown in C–E. **P < 0.01 and ***P < 0.001 using repeated measures one-way ANOVA followed by Tukey’s multiple comparisons test. Error bars show ± SEM.

Copyright © 2022 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts